Join Growin Stock Community!

Sonoma pharmaceuticals, inc.SNOA.US Overview

US StockHealthcare
(No presentation for SNOA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SNOA AI Insights

SNOA Overall Performance

SNOA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SNOA Recent Performance

0.69%

Sonoma pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

SNOA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SNOA Key Information

SNOA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SNOA Profile

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

Price of SNOA

SNOA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SNOA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.95
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.28
PB Ratio
1.46
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
38.16%
Net Margin
-19.02%
Revenue Growth (YoY)
26.83%
Profit Growth (YoY)
34.49%
3-Year Revenue Growth
13.89%
3-Year Profit Growth
25.69%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.95
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.28
PB Ratio
1.46
Price-to-FCF
-
Gross Margin
38.16%
Net Margin
-19.02%
Revenue Growth (YoY)
26.83%
Profit Growth (YoY)
34.49%
3-Year Revenue Growth
13.89%
3-Year Profit Growth
25.69%

  • When is SNOA's latest earnings report released?

    The most recent financial report for Sonoma pharmaceuticals, inc. (SNOA) covers the period of 2026Q3 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SNOA's short-term business performance and financial health. For the latest updates on SNOA's earnings releases, visit this page regularly.

  • What is the operating profit of SNOA?

    According to the latest financial report, Sonoma pharmaceuticals, inc. (SNOA) reported an Operating Profit of -678K with an Operating Margin of -15.59% this period, representing a growth of 34.24% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is SNOA's revenue growth?

    In the latest financial report, Sonoma pharmaceuticals, inc. (SNOA) announced revenue of 4.35M, with a Year-Over-Year growth rate of 22.03%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does SNOA have?

    As of the end of the reporting period, Sonoma pharmaceuticals, inc. (SNOA) had total debt of 655K, with a debt ratio of 0.05. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SNOA have?

    At the end of the period, Sonoma pharmaceuticals, inc. (SNOA) held Total Cash and Cash Equivalents of 2.56M, accounting for 0.19 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does SNOA go with three margins increasing?

    In the latest report, Sonoma pharmaceuticals, inc. (SNOA) did not achieve the “three margins increasing” benchmark, with a gross margin of 37.9%%, operating margin of -15.59%%, and net margin of -18.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess SNOA's profit trajectory and future growth potential.

  • Is SNOA's EPS continuing to grow?

    According to the past four quarterly reports, Sonoma pharmaceuticals, inc. (SNOA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.48. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SNOA?

    Sonoma pharmaceuticals, inc. (SNOA)'s Free Cash Flow (FCF) for the period is -811K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 244.05% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SNOA?

    The latest valuation data shows Sonoma pharmaceuticals, inc. (SNOA) has a Price-To-Earnings (PE) ratio of -1.44 and a Price/Earnings-To-Growth (PEG) ratio of -0.04. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.